Switch theme
Sign up to access all valuation multiples
Cuorips Inc is engaged in the Research, development, manufacturing, and sales of Cellular and Tissue-based Products and Cell processing products. The company is also engaged in Contract development and manufacturing services and consulting services of Cellular and Tissue-based Products and Cell processing product.
2017
43
LTM Revenue n/a
LTM EBITDA n/a
$418M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Cuorips has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Cuorips achieved revenue of $0.2M and an EBITDA of -$3.4M.
Cuorips expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Cuorips valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.3M | $0.2M | XXX | XXX | XXX |
| Gross Profit | $0.1M | $0.1M | XXX | XXX | XXX |
| Gross Margin | 28% | 91% | XXX | XXX | XXX |
| EBITDA | -$2.5M | -$3.4M | XXX | XXX | XXX |
| EBITDA Margin | -971% | -2244% | XXX | XXX | XXX |
| Net Profit | -$2.5M | -$3.0M | XXX | XXX | XXX |
| Net Margin | -981% | -1957% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Cuorips's stock price is JPY 8450 (or $56).
Cuorips has current market cap of JPY 67.7B (or $450M), and EV of JPY 62.9B (or $418M).
See Cuorips trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $418M | $450M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Cuorips has market cap of $450M and EV of $418M.
Cuorips's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Cuorips's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Cuorips and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $418M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpCuorips's NTM/LTM revenue growth is n/a
Cuorips's revenue per employee for the last fiscal year averaged $4K, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Cuorips's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Cuorips's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Cuorips and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -40% | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | 39% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $4K | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 2589% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Lineage Cell Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Arovella Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Aroa Biosurgery | XXX | XXX | XXX | XXX | XXX | XXX |
| Cynata Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Mesoblast | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Cuorips acquired XXX companies to date.
Last acquisition by Cuorips was XXXXXXXX, XXXXX XXXXX XXXXXX . Cuorips acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Cuorips founded? | Cuorips was founded in 2017. |
| Where is Cuorips headquartered? | Cuorips is headquartered in Japan. |
| How many employees does Cuorips have? | As of today, Cuorips has 43 employees. |
| Is Cuorips publicy listed? | Yes, Cuorips is a public company listed on TKS. |
| What is the stock symbol of Cuorips? | Cuorips trades under 4894 ticker. |
| When did Cuorips go public? | Cuorips went public in 2023. |
| Who are competitors of Cuorips? | Similar companies to Cuorips include e.g. Lineage Cell Therapeutics, Arovella Therapeutics, Aroa Biosurgery, Cynata Therapeutics. |
| What is the current market cap of Cuorips? | Cuorips's current market cap is $450M |
| What is the current revenue growth of Cuorips? | Cuorips revenue growth between 2023 and 2024 was -40%. |
| Is Cuorips profitable? | Yes, Cuorips is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
